rs-0139
Solid Tumors
RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.Phase 1Active
CC
40/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 65/ 100
Competitive context
927 Active assets in the Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
PANITUMUMAB Astellas Pharma Inc | Phase 2 | BBB |
GRANULOCYTE COLONY-STIMULATING FACTOR LENOGRASTIM Sanofi | Phase 4 | BB |
Bxcl501 Medical College of Wisconsin | Phase 4 | BB |
VITAMIN D Tanta University | Phase 4 | BB |
LIDOCAINE Medical College of Wisconsin | Phase 4 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →